Nanosonics Limited

ASX:NAN Stock Report

Market Cap: AU$1.0b

Nanosonics Valuation

Is NAN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NAN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: NAN (A$3.54) is trading below our estimate of fair value (A$5.01)

Significantly Below Fair Value: NAN is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NAN?

Key metric: As NAN is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for NAN. This is calculated by dividing NAN's market cap by their current earnings.
What is NAN's PE Ratio?
PE Ratio82.8x
EarningsAU$12.97m
Market CapAU$1.05b

Price to Earnings Ratio vs Peers

How does NAN's PE Ratio compare to its peers?

The above table shows the PE ratio for NAN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average44.7x
ANN Ansell
39.6x22.8%AU$4.7b
SDI SDI
11.6x17.8%AU$121.2m
PGC Paragon Care
98.8x35.6%AU$827.7m
ACL Australian Clinical Labs
28.9x16.0%AU$692.4m
NAN Nanosonics
82.8x24.0%AU$1.1b

Price-To-Earnings vs Peers: NAN is expensive based on its Price-To-Earnings Ratio (82.8x) compared to the peer average (40.8x).

Price to Earnings Ratio vs Industry

How does NAN's PE Ratio compare vs other companies in the Global Medical Equipment Industry?

10 CompaniesPrice / EarningsEstimated GrowthMarket Cap
NAN 82.8xIndustry Avg. 28.0xNo. of Companies48PE020406080100+
10 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: NAN is expensive based on its Price-To-Earnings Ratio (82.8x) compared to the Global Medical Equipment industry average (28x).

Price to Earnings Ratio vs Fair Ratio

What is NAN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NAN PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio82.8x
Fair PE Ratio40x

Price-To-Earnings vs Fair Ratio: NAN is expensive based on its Price-To-Earnings Ratio (82.8x) compared to the estimated Fair Price-To-Earnings Ratio (40.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NAN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentAU$3.54
AU$3.46
-2.2%
11.2%AU$4.00AU$2.75n/a10
Nov ’25AU$3.20
AU$3.53
+10.3%
12.1%AU$4.20AU$2.75n/a11
Oct ’25AU$3.69
AU$3.53
-4.4%
12.1%AU$4.20AU$2.75n/a11
Sep ’25AU$3.23
AU$3.48
+7.8%
12.5%AU$4.20AU$2.75n/a12
Aug ’25AU$3.20
AU$3.33
+4.2%
16.8%AU$4.20AU$2.55n/a12
Jul ’25AU$2.87
AU$3.20
+11.6%
16.4%AU$4.20AU$2.55n/a12
Jun ’25AU$2.81
AU$3.20
+14.0%
16.4%AU$4.20AU$2.55n/a12
May ’25AU$2.83
AU$3.20
+13.2%
16.4%AU$4.20AU$2.55n/a12
Apr ’25AU$2.75
AU$3.20
+16.5%
16.4%AU$4.20AU$2.55n/a12
Mar ’25AU$2.77
AU$3.20
+15.7%
16.4%AU$4.20AU$2.55n/a12
Feb ’25AU$2.90
AU$3.75
+29.3%
15.6%AU$5.00AU$2.83n/a11
Jan ’25AU$4.40
AU$4.56
+3.7%
14.7%AU$5.46AU$3.65n/a12
Dec ’24AU$4.11
AU$4.65
+13.2%
17.9%AU$6.50AU$3.65n/a12
Nov ’24AU$3.86
AU$4.65
+20.5%
17.9%AU$6.50AU$3.65AU$3.2012
Oct ’24AU$4.22
AU$4.69
+11.2%
17.1%AU$6.50AU$3.75AU$3.6912
Sep ’24AU$4.15
AU$4.59
+10.6%
18.6%AU$6.50AU$3.34AU$3.2313
Aug ’24AU$4.78
AU$4.76
-0.3%
17.9%AU$6.50AU$3.34AU$3.2013
Jul ’24AU$4.74
AU$4.72
-0.4%
19.1%AU$6.50AU$3.34AU$2.8712
Jun ’24AU$5.17
AU$4.72
-8.6%
19.1%AU$6.50AU$3.34AU$2.8112
May ’24AU$5.54
AU$4.71
-15.0%
18.8%AU$6.50AU$3.34AU$2.8312
Apr ’24AU$5.09
AU$4.54
-10.7%
15.5%AU$6.00AU$3.34AU$2.7512
Mar ’24AU$4.46
AU$4.45
-0.2%
12.9%AU$5.35AU$3.34AU$2.7712
Feb ’24AU$4.81
AU$4.47
-7.0%
14.3%AU$5.50AU$3.25AU$2.9011
Jan ’24AU$4.29
AU$4.32
+0.7%
16.4%AU$5.50AU$3.25AU$4.4011
Dec ’23AU$4.84
AU$4.32
-10.7%
16.4%AU$5.50AU$3.25AU$4.1111
Nov ’23AU$4.27
AU$4.25
-0.4%
17.6%AU$5.50AU$3.25AU$3.8611

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

SDI

AU$122.4m

Engages in the research and development, manufacture, and marketing of dental restorative materials, whitening systems, and other dental materials in Australia, Europe, the United States, and Brazil.

SDI

AU$1.02

7D

0%

1Y

22.9%

Doctor Care Anywhere Group

AU$25.7m

Provides digital healthcare and development services in the United Kingdom, Australia, and the Republic of Ireland.

DOC

AU$0.065

7D

-3.0%

1Y

32.7%

Nova Eye Medical

AU$36.6m

Designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally.

EYE

AU$0.16

7D

3.2%

1Y

14.3%